Biomarkers of Synaptic Damage in Multiple Sclerosis
Identification of New Biomarkers Useful to Define the Course of Multiple Sclerosis and Study of the Mechanisms That Promote Synaptic Damage
Neuromed IRCCS
300 participants
Nov 22, 2017
OBSERVATIONAL
Conditions
Summary
A prospective and retrospective cohort study of about five years will be performed on blood and cerebrospinal fluid samples taken for diagnostic reasons from recruited patients within the Neuromed Neurology Unit. Subjects with other chronic neurodegenerative diseases such as Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and Parkinson's disease (PD), and healthy subjects subjected to blood sampling and / or lumbar puncture for clinical reasons will be recruited As control groups.
Eligibility
Inclusion Criteria4
- Male and female patients (age between 18 and 65 years)
- Diagnosis of MS in accordance with McDonald's (2010 rev) criteria,
- EDSS between 0 and 5.5 (included),
- Patients able to provide informed consent to participation in the study
Exclusion Criteria5
- Inability to provide informed written consent
- Altered basal blood count
- Pregnancy or lactation
- Contraindications for the execution of magnetic resonance imaging with gadolinium
- Significant clinical conditions in addition to SM or other chronic neurodegenerative diseases including latent viral infections
Interventions
lumbar puncture performed to detect OCB for diagnostic purposes
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03217396